This page uses content from Wikipedia and is licensed under CC BY-SA.

Savolitinib

Savolitinib
Savolitinib.svg
Clinical data
Other namesVolitinib
Identifiers
CAS Number
ChemSpider
KEGG
ECHA InfoCard100.238.920 Edit this at Wikidata
Chemical and physical data
FormulaC17H15N9
Molar mass345.370 g·mol−1
3D model (JSmol)

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2]

References

  1. ^ [searchusan.ama-assn.org]
  2. ^ adisinsight.springer.com/drugs/800035893